UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/600/0.1/14.01.26 | Real-time BOERSE MUENCHEN 05:40:59 2024-06-05 EDT | ||
| 4.19 EUR | 0.00% |
|
| Current month | +20.40% | ||
| 1 month | +117.10% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-05 | 4.19 | 0.00% |
| 24-06-04 | 4.19 | +10.85% |
| 24-06-03 | 3.78 | +8.62% |
| 24-05-31 | 3.48 | +13.73% |
| 24-05-30 | 3.06 | -3.47% |
Real-time BOERSE MUENCHEN
Last update June 05, 2024 at 05:40 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD290Y |
| ISIN | DE000HD290Y6 |
| Date issued | 2024-01-29 |
| Strike | 600 $ |
| Maturity | 2026-01-14 (589 Days) |
| Parity | 10 : 1 |
| Emission price | 3.51 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.19 € |
|---|---|
| Lowest since issue | 1.72 € |
| Spread | 0.14 € |
| Spread % | 3.29% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
475
USD
Average target price
463.5
USD
Spread / Average Target
-2.41%
- Stock Market
- Warrants
- Warrant
